Product Information
DEPAKOTE DR 250 MG TABLET is a brand product labeled by AbbVie Inc., priced at $4.0456 per EA under NDC 00074732613. Its NADAC has been published 167 times since Jul 26, 2023.
FDA first approved this application on Mar 10, 1983. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Divalproex Sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/1
Manufacturer
AbbVie Inc.NDC
00074732613
Classification
Brand
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DIVALPROEX SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA018723FDA Approved
3/10/1983
TE Code
AB
On Market Since
6/30/2023
Pharmacological Classes
Price Statistics
The NADAC for DEPAKOTE DR 250 MG TABLET has been published 167 times since Jul 26, 2023, and over the history we have for it it has risen 15.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.0456 per EA |
|---|---|
| All-time high | $4.0499 (Jun 10, 2026) |
| All-time low | $3.5136 (Jul 26, 2023) |
| 52-week high | $4.0499 |
| 52-week low | $3.8506 |
| Median price | $3.8462 |
| Average price | $3.7980 |
| Largest weekly change | +5.0% (Jan 10, 2024) |
| Weeks tracked | 167 |
| Tracking since | Jul 26, 2023 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Divalproex Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEPAKOTE DR 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DEPAKOTE DR 250 MG TABLET, manufactured by AbbVie Inc., is $4.0456 per EA (NDC 00074732613), effective Sep 30, 2026.
How has the price of DEPAKOTE DR 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for DEPAKOTE DR 250 MG TABLET has risen 15.1%. It has been tracked across 167 weekly CMS publications since Jul 26, 2023.
What are the highest and lowest recorded NADAC prices for DEPAKOTE DR 250 MG TABLET?
Since Jul 26, 2023, the NADAC for DEPAKOTE DR 250 MG TABLET has ranged from a low of $3.5136 (Jul 26, 2023) to a high of $4.0499 (Jun 10, 2026), with a median of $3.8462 per EA.
Are there cheaper alternatives to DEPAKOTE DR 250 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DIVALPROEX SOD DR 250 MG TAB, is $0.0833 per EA — about 98% below DEPAKOTE DR 250 MG TABLET.
Who manufactures DEPAKOTE DR 250 MG TABLET?
DEPAKOTE DR 250 MG TABLET (NDC 00074732613) is labeled by AbbVie Inc., and CMS classifies it as a brand product.